File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?

TitleIs there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?
Authors
Issue Date2012
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
Citation
Annals of Surgical Oncology, 2012, v. 19 n. 11, p. 3479-3485 How to Cite?
AbstractBACKGROUND: In the follow-up of papillary thyroid cancer (PTC) patients treated with curative thyroidectomy and radioiodine ablation, raised thyroglobulin (Tg) predicts recurrence with reasonable sensitivity and specificity. However, a proportion of patients present with raised Tg level but no other clinical evidence of disease. Only limited data on Tg kinetics have been reported to date. Here we aim to evaluate the prognostic and predictive significance of nonstimulated serum Tg velocity (TgV). METHODS: Consecutive PTC patients treated with curative thyroidectomy and radioiodine ablation between 2003 and 2010 were analyzed. Patients with at least one detectable Tg measurement (>0.2 ng/mL) were included. TgV was defined as the annualized rate of Tg change. Logistic regression analyses were performed to evaluate the role of TgV in the prediction of disease recurrence. The optimal TgV cutoff was assigned by receiver-operating characteristic curve analysis. Overall survival of patients above versus below the TgV cutoff were determined by the Kaplan-Meier method and compared. RESULTS: Of a total of 501 patients, 87 had at least one Tg value >0.2 ng/mL; in these latter patients, 29 (33.3 %) developed recurrence. TgV was an independent predictor of the recurrence. TgV >/=0.3 ng/mL per year predicted recurrence with a sensitivity of 83.3 % and specificity of 94.4 %. Patients with TgV below the cutoff had a significantly better overall survival (p = 0.038). CONCLUSIONS: TgV predicts recurrence with high sensitivity and specificity, and is a prognosticator of survival in postthyroidectomy and postablation PTC patients with raised Tg.
Persistent Identifierhttp://hdl.handle.net/10722/149151
ISSN
2015 Impact Factor: 3.655
2015 SCImago Journal Rankings: 1.902
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Hen_HK
dc.contributor.authorWong, KPen_HK
dc.contributor.authorYau, Ten_HK
dc.contributor.authorTang, Ven_HK
dc.contributor.authorLeung, Ren_HK
dc.contributor.authorChiu, Jen_HK
dc.contributor.authorLang, BHHen_HK
dc.date.accessioned2012-06-22T06:27:00Z-
dc.date.available2012-06-22T06:27:00Z-
dc.date.issued2012en_HK
dc.identifier.citationAnnals of Surgical Oncology, 2012, v. 19 n. 11, p. 3479-3485en_HK
dc.identifier.issn1068-9265en_HK
dc.identifier.urihttp://hdl.handle.net/10722/149151-
dc.description.abstractBACKGROUND: In the follow-up of papillary thyroid cancer (PTC) patients treated with curative thyroidectomy and radioiodine ablation, raised thyroglobulin (Tg) predicts recurrence with reasonable sensitivity and specificity. However, a proportion of patients present with raised Tg level but no other clinical evidence of disease. Only limited data on Tg kinetics have been reported to date. Here we aim to evaluate the prognostic and predictive significance of nonstimulated serum Tg velocity (TgV). METHODS: Consecutive PTC patients treated with curative thyroidectomy and radioiodine ablation between 2003 and 2010 were analyzed. Patients with at least one detectable Tg measurement (>0.2 ng/mL) were included. TgV was defined as the annualized rate of Tg change. Logistic regression analyses were performed to evaluate the role of TgV in the prediction of disease recurrence. The optimal TgV cutoff was assigned by receiver-operating characteristic curve analysis. Overall survival of patients above versus below the TgV cutoff were determined by the Kaplan-Meier method and compared. RESULTS: Of a total of 501 patients, 87 had at least one Tg value >0.2 ng/mL; in these latter patients, 29 (33.3 %) developed recurrence. TgV was an independent predictor of the recurrence. TgV >/=0.3 ng/mL per year predicted recurrence with a sensitivity of 83.3 % and specificity of 94.4 %. Patients with TgV below the cutoff had a significantly better overall survival (p = 0.038). CONCLUSIONS: TgV predicts recurrence with high sensitivity and specificity, and is a prognosticator of survival in postthyroidectomy and postablation PTC patients with raised Tg.en_HK
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.orgen_HK
dc.relation.ispartofAnnals of Surgical Oncologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleIs there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?en_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailLang, BHH: blang@hkucc.hku.hk-
dc.identifier.authorityYau, T=rp01466en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1245/s10434-012-2391-6en_HK
dc.identifier.pmid22576067-
dc.identifier.pmcidPMC3442160-
dc.identifier.scopuseid_2-s2.0-84868214910en_HK
dc.identifier.hkuros199997en_US
dc.identifier.volume19-
dc.identifier.issue11-
dc.identifier.spage3479en_HK
dc.identifier.epage3485en_HK
dc.identifier.isiWOS:000308737100027-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, H=55190101300en_HK
dc.identifier.scopusauthoridWong, KP=24443029700en_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridTang, V=55214483700en_HK
dc.identifier.scopusauthoridLeung, R=52364352500en_HK
dc.identifier.scopusauthoridChiu, J=36887309300en_HK
dc.identifier.scopusauthoridLang, BHH=7201907327en_HK
dc.identifier.citeulike10687967-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats